Vornado Realty Trust (VNO) Financials Nov 17, 2014, 4:48

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Vornado Realty Trust (VNO) Financials Nov 17, 2014, 4:48 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Vornado Realty Trust


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 2.65B 2.74B 2.88B 2.72B 2.71B
Total Investment Income 3.83M 22.6M 10.41M 3.58M 50.59M
Sundry Revenue/Income 2.57B 2.64B 2.79B 2.61B 2.57B
Trading Account Income - - - - -
Trust Income, Commissions & Fees 69.97M 78.17M 81.86M 110.34M 91.14M
Commission & Fee Income 69.97M 78.17M 81.86M 110.34M 91.14M
Total Expense 2.57B 2.15B 2.44B 2.44B 2.22B
Total Interest Expense 634.28M 560.27M 544.02M 500.36M 483.19M
Depreciation & Amortization Expense 467.02M 464.5M 491.37M 463.62M 478.35M
Other Operating Expense 0 (123.21M) 7.28M 31.7M (27.43M)
2009 2010 2011 2012 2013 5-year trend
Operating Income 80.22M 581.71M 444.18M 285.32M 491.79M
Non-Operating Income (Expense) 142.46M 196.9M 181.86M 465.89M (340.14M)
Non-Operating Interest Income 68.26M 44.01M 51.44M 33M 32.37M
Miscellaneous Non Operating Expense 1.81M 58.83M 10.11M 9.77M (33.73M)
Equity in Affiliates (Pretax) 72.39M 94.06M 120.31M 423.13M (338.79M)
Unusual Expense 125.4M 27.72M 6.75M 334.48M 17.82M
Pretax Income 97.28M 750.89M 619.29M 416.73M 133.82M
Income Taxes 20.74M 22.48M 24.83M 8.13M (6.41M)
Income Tax - Current - Domestic - - - - -
Income Tax - Current - Foreign - - - - -
Income Tax - Deferred - Domestic - - - - -
Income Tax - Deferred - Foreign - - - - -
Income Tax Credits - - - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) (184,000) 4.26M 4.78M 8.75M (1.24M)
Consolidated Net Income 76.36M 732.67M 599.25M 417.35M 138.99M
Minority Interest Expense 18.87M 60.12M 68.88M 61.21M 62.03M
Net Income 57.5M 672.55M 530.36M 356.14M 76.95M
Extraordinaries & Discontinued Operations 48.49M (20.41M) 136.72M 269.87M 397.78M
Extra Items & Gain/Loss Sale Of Assets 45.28M 2.51M 135.53M 265.46M 414.5M
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 3.21M (22.91M) 1.19M 4.41M (16.72M)
Net Income After Extraordinaries 9.01M 692.96M 393.65M 86.27M (320.83M)
Preferred Dividends 57.08M 55.53M 65.53M 76.94M 82.81M
Net Income Available to Common 419,000 617.02M 464.83M 279.2M (5.85M)
EPS (Basic) 0.02 3.26 2.53 1.53 (0.12)
Basic Shares Outstanding 171.6M 182.34M 184.31M 185.81M 186.94M
EPS (Diluted) 0.02 3.23 2.51 1.52 (0.12)
Diluted Shares Outstanding 173.5M 184.16M 186.02M 186.53M 187.71M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 9

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

A Comprehensive Look at Apple's Competitive Position in Tech

Updated Category News Views 313

Understanding Apple's Competitive Landscape In today's dynamic business environment, a deep-dive analysis of top companies is essential for investors and industry insiders. This examination will focus on Apple (AAPL), alongside its chief rivals in the Technology Hardware, Storage & Peripherals sector. By analyzing crucial financial indicators, market positioning, and...

Continue Reading
Cegedim Shares Insights on Latest Liquidity Contract Performance

Updated Category News Views 135

Overview of Cegedim's Liquidity Contract Statement This article covers the latest updates on Cegedim’s liquidity contract performance, highlighting significant figures and trends that reflect the company's financial health. Cegedim has established a robust liquidity contract with Rothschild Martin Maurel, aimed at promoting transparency and liquidity in its shares. Key...

Continue Reading
Silexion Therapeutics Advances SIL204 for Pancreatic Cancer

Updated Category News Views 136

Silexion Therapeutics Moves Forward with SIL204 Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the...

Continue Reading
Emerson Partners with LifeSight for Enhanced Pension Solutions

Updated Category News Views 178

Emerson Partners with LifeSight for Pension Solutions LifeSight, WTW’s UK defined contribution (DC) master trust, has stepped into a significant role by becoming the full master trust provider for Emerson, the advanced electronics powerhouse. This partnership aims to cover all active, deferred, and drawdown members effectively, ensuring they are well-accommodated in...

Continue Reading
Howard Marks Joins Alliance for Decision Education Board

Updated Category News Views 227

Exciting News from the Alliance for Decision Education The Alliance for Decision Education is thrilled to announce an important addition to its Board of Directors. Howard Marks, a leader in investment management and a well-respected voice in decision-making, has agreed to join the board. As the co-chairman and co-founder of Oaktree Capital Management, Marks brings with...

Continue Reading